Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (MX:BMY) — Drug Manufacturers - General. Antal børser, hvor selskabets aktier handles: 6. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- bms.com
- Investorrelationer
- bms.com/investors.html
- Sektor
- Healthcare · Drug Manufacturers - General
- Hovedkontor
- PRINCETON, United States
- Administrerende Direktør
- Christopher S. Boerner
- Ansatte
- 32 500
- Grundlagt
- 1989
- Børsnoteret Siden
- 01.03.2005 (MX:BMY)
- Udestående Aktier
- 2.04 mia. pr. 2026-07-22
- Free Float
- 2.04 mia.
- Markedsværdi
- 128.41 mia. USD
- Insidere
- 0.1%
- Institutionelle Investorer
- 84.87%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk Form
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- Udbetalingsgrad
- 54.9%
- FCF
- 11.4 mia. USD45%
- Gæld
- 43.9 mia. USD3.1 år FCF
- Udbyttestreak
- 54 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
Beskrivelse
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Børser og Tickere
| Børs | Ticker | Valuta | Pris | Type |
|---|---|---|---|---|
| US USA Stocks | BMY primær | USD | 59.12 -0.77% | almindelige aktier |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | almindelige aktier |
| MI Borsa Italiana (Milan) | 1BMY sekundær | EUR | 53.13 +0.28% | almindelige aktier |
| MX Mexican Stock Exchange | BMY sekundær | MXN | 1 047 -3.81% | almindelige aktier |
| VI Vienna Stock Exchange | BMYS sekundær | EUR | 52.98 +0.34% | almindelige aktier |
| XETRA Xetra | BRM sekundær | EUR | 53.04 +0.89% | almindelige aktier |
Udbytte
Bristol-Myers Squibb Company (BMY) udbetaler udbytte kvartalsvis. Pr. År (12 måneder op til og med den senest annoncerede betaling): 45.2778 MXN pr. Aktie (betalinger: 4). Det svarer til cirka 4.32% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 04.01.2027. Uafbrudt udbyttehistorik: 54 år.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-10-02 | — | 11.3195 MXN | 1.1/4.3 % | kvartalsvis | MX:BMY |
| 2026-07-02 | — | 11.3195 MXN | 1.1/4.3 % | kvartalsvis | MX:BMY |
| 2026-04-06 | — | 11.3195 MXN | 1.1/4.3 % | kvartalsvis | MX:BMY |
| 2026-01-02 | — | 11.3195 MXN | 1.1/4.3 % | kvartalsvis | MX:BMY |
| 2025-10-03 | — | 11.1398 MXN | 1.1/4.3 % | kvartalsvis | MX:BMY |
| 2025-07-03 | — | 11.1398 MXN | 1.1/4.2 % | kvartalsvis | MX:BMY |
| 2025-04-04 | — | 11.1398 MXN | 1.1/4.2 % | kvartalsvis | MX:BMY |
| 2025-01-03 | — | 11.1398 MXN | 1.1/4.2 % | kvartalsvis | MX:BMY |
| 2024-10-04 | — | 10.7804 MXN | 1.0/4.1 % | kvartalsvis | MX:BMY |
| 2024-07-05 | — | 10.7804 MXN | 1.0/4.1 % | kvartalsvis | MX:BMY |
| 2024-04-04 | — | 10.7804 MXN | 1.0/4.0 % | kvartalsvis | MX:BMY |
| 2024-01-04 | — | 10.7804 MXN | 1.0/4.0 % | kvartalsvis | MX:BMY |
| 2023-10-05 | — | 10.2414 MXN | 1.0/3.9 % | kvartalsvis | MX:BMY |
| 2023-07-06 | — | 10.2414 MXN | 1.0/3.9 % | kvartalsvis | MX:BMY |
| 2023-04-10 | — | 10.2414 MXN | 1.0/3.8 % | kvartalsvis | MX:BMY |
| 2023-01-05 | — | 10.2414 MXN | 1.0/3.8 % | kvartalsvis | MX:BMY |
| 2022-10-06 | — | 9.7024 MXN | 0.9/3.7 % | kvartalsvis | MX:BMY |
| 2022-06-30 | — | 9.7024 MXN | 0.9/2.8 % | kvartalsvis | MX:BMY |
| 2022-03-31 | — | 9.7024 MXN | 0.9/1.9 % | kvartalsvis | MX:BMY |
| 2022-01-06 | — | 9.7024 MXN | 0.9/0.9 % | kvartalsvis | MX:BMY |
Nyheder Denne Uge
Pressemeddelelser fra virksomhedens investorhjemmeside, opdateret dagligt. Links fører til virksomhedens hjemmeside. Overskrifterne er på originalsproget, som på virksomhedens hjemmeside.
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 mio. | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 mio. | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 mio. | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 mio. | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 mio. | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 mio. | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 mio. | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 mio. | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 mio. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 mio. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 mio. | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 mio. | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 mio. | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
